Autoimmune Disease Diagnostics Market size to exceed $2,013mn by 2030

Autoimmune Disease Diagnostics Market size is set to reach USD 2,013 million by 2030, according to a new research report by Global Market Insights Inc.
 

High incidence and prevalence of autoimmune diseases, growing awareness about autoimmune diseases, supportive government policies for research activities on autoimmune diseases and increasing adoption of lab automation technologies, are some of the factors that are anticipated to affect the adoption of the autoimmune disease diagnostics assertively.
 

Growing awareness about autoimmune diseases to spur the autoimmune disease diagnostics market statistics

Autoimmune diseases are the class of diseases wherein the immune cells of the body exert immunogenic response against its own healthy cells. Autoimmune disorders can be innate or acquired. Many government and non-government organizations come together to take initiative in spreading awareness about the autoimmune disorders. March is taken as National Autoimmune Diseases Awareness Month by American Autoimmune Related Diseases Association (AARDA), an organization that collaborates with other organizations and healthcare centers to improve healthcare and research in the field. It is working towards public awareness around prevalence and other essential factors that surrounds autoimmune diseases.
 

Rising prevalence of localized autoimmune diseases will augment the autoimmune disease diagnostics market outlook

Localized autoimmune disease segment exceeded USD 777 million in 2021. This is owing to the increasing prevalence of the localized autoimmune diseases such as type 1 diabetes mellites. As per a recent report cited by the WHO, around 9 million people were affected by type 1 diabetes in 2021. With the rise in prevalence of such autoimmune diseases, the adoption of autoimmune disease diagnostics also rises.
 

Browse key industry insights spread across 190 pages with 292 market data tables & 17 figures & charts from the report, “Autoimmune Disease Diagnostics Market Analysis By Disease Type (Systemic Autoimmune Disease {Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Multiple Sclerosis}, Localized Autoimmune Disease {Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid), Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), End-use (Hospitals, Diagnostic Centers), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/autoimmune-disease-diagnostics-market
 

Autoantibody tests has increased the demand for autoimmune disease diagnostics

Autoantibody tests segment is set to reach over USD 650 million by 2030. This is due to the increasing prevalence of autoantibody disorders such as rheumatoid arthritis. As per a recent study updated in the UpToDate Journal, RA affects over 0.24 to 1 percent of the population and is more prevalent in women than in men and occurs in 40 per 100,000 people in the U.S. and northern European countries.
 

Growing healthcare investments accelerates the number of diagnostic centers thereby spurring market revenue

autoimmune disease diagnostics market from diagnostic centers segment is anticipated to surpass USD 831 million by 2030. Diagnostic centers are medical facilities that offer diagnostic services through medical professionals to the general public. These facilities have equipment and supplies to perform specialized tests to investigate a concerning symptom and monitor an existing health condition. An exponential rise in the healthcare expenditure has assertively impacted the rise in the number of healthcare facilities, including diagnostic centers. Moreover, the need for immediate professional attention with an ease of convenience in diagnosis are the factors that help the diagnostic centers segment to grow.
 

Increasing demand for autoimmune disease diagnostics in Germany is projected to fuel the autoimmune disease diagnostics market expansion

Germany market is projected to exceed USD 114 million by 2030. This is attributed to the increasing prevalence of autoimmune diseases and the rise in healthcare expenditure to help combat the diseases. Subsequently, the rise in the healthcare expenditure have assertively contributed to the therapeutics and diagnostics of the autoimmune diseases. Furthermore, the rising awareness pertaining to autoimmune diseases have added to the rise in adoption of the autoimmune disease diagnostics.
 

Players are emphasizing on strategic initiatives and innovative product launches to expand business operations

Some of the major players operating in the autoimmune disease diagnostics industry are Abbott Laboratories, Siemens Healthcare, Bio-rad Laboratories, F. Hoffmann-la Roche, Thermo Fisher Scientific, and EUROIMMUN Medizinische Labordiagnostika AG (Perkin Elmer) among others. These industry players are engaged in strategic collaborations, partnerships, and agreements to gain competitive advantage over their competitors.
 

For instance, in September 2019, MedGenome Labs announced the launch of Immucare, the first diagnostic lab for autoimmune diseases in India in partnership with Care Hospital, Kochi. Such initiatives help in promoting lucrative growth opportunity to the market.